BioNTech (BNTX), once thrust into the global limelight alongside Pfizer with their blockbuster COVID-19 vaccine Comirnaty, is now navigating a decisive strategic pivot. As vaccination rates tumble and tighter market regulations take hold, the company’s coronavirus business has faded. The silver lining: BioNTech’s future no longer hinges on that franchise. Instead, it has set its sights on a far larger arena — oncology. The pressing question is whether its cancer-fighting assets can power a comeback.
Oncology remains the pharmaceutical industry’s largest therapeutic field, and for good reason. Cancer is one of the world’s leading causes of death; roughly one in three people in the United States will be diagnosed with the disease in their lifetime. The vast unmet need translates into a massive market, with many cancer subtypes still lacking effective treatments — a gap that keeps drawing drugmakers.
Because cancer is life-threatening, regulators frequently grant experimental therapies special designations to speed up approvals, adding further incentive. Cancer drugs also tend to command high prices and can be administered for years. By one estimate, the global cancer therapeutics market will expand to $516.2 billion by 2035, growing at a compound annual rate of 9.3%. That is the landscape BioNTech is determined to carve a meaningful place in.
The company is not tiptoeing in. It already has more than 25 oncology clinical trials in phase 2 or phase 3, a pipeline depth that suggests multiple shots at approval. The brightest spotlight falls on pumitamig, a bispecific antibody co-developed with Bristol Myers Squibb. Unlike conventional antibodies, bispecifics bind two different targets at once, potentially marshaling the immune system against cancer more effectively. Pumitamig has been touted by some as a potential “Keytruda killer” — a next-generation therapy that could challenge the world’s top-selling cancer drug. It is being studied across lung, kidney, breast, liver, colorectal and other cancers, and could secure approval within a few years, with eventual annual sales expected to surpass $1 billion. And that is just one oncology candidate.
Beyond cancer, BioNTech is also advancing vaccines for tuberculosis and HIV, further testing the versatility of its platform.
Yet the question of whether BioNTech can return to its former heights is not just about pipeline potential — it is also a matter of valuation. At recent prices, the company’s market capitalization stands at roughly $23.2 billion, while trailing 12-month revenue was just $3.3 billion and sales are declining. The business is not yet consistently profitable. Markets are clearly pricing in a great deal of faith in its R&D pipeline. That works as long as development stays on track, but any clinical or regulatory stumble could send the share price tumbling. Running a pipeline of this magnitude without encountering at least some setbacks is extraordinarily difficult for any biotech.
BioNTech’s oncology story is genuinely compelling. Yet at current levels, the risk-reward equation looks lopsided. Whether its cancer “ace” can write a return-to-glory script will ultimately depend on the data emerging from labs and clinical trials — and for cautious investors, waiting for a more attractive entry point might be the wiser move.
